Insulet Corporation $PODD Stock Position Trimmed by First Light Asset Management LLC

Key Points

• First Light Asset Management LLC significantly reduced its holdings in Insulet Corporation by 49.7%, owning 17,022 shares worth approximately $4.47 million after selling 16,799 shares in Q1.
• Insulet's stock has seen positive momentum, opening at $339.88, with a recent increase in target prices from multiple analysts, highlighting strong earnings performance over the past quarter.
• The company's latest earnings report revealed a 32.9% revenue increase year-over-year, with reported earnings of $1.17 per share, exceeding analysts' expectations of $0.92 per share.

First Light Asset Management LLC reduced its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 49.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 17,022 shares of the medical instruments supplier's stock after selling 16,799 shares during the period. First Light Asset Management LLC's holdings in Insulet were worth $4,470,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after acquiring an additional 178,976 shares during the last quarter. American Century Companies Inc. raised its stake in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Groupama Asset Managment raised its stake in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after acquiring an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after acquiring an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after acquiring an additional 661,717 shares during the last quarter.

Insulet Trading Up 0.6%

Shares of PODD stock traded up $1.96 during mid-day trading on Friday, hitting $348.43. 498,473 shares of the company's stock were exchanged, compared to its average volume of 584,368. The stock has a market cap of $24.53 billion, a price-to-earnings ratio of 105.91, a PEG ratio of 2.90 and a beta of 1.36. The stock has a 50-day simple moving average of $307.55 and a two-hundred day simple moving average of $289.82. Insulet Corporation has a fifty-two week low of $211.27 and a fifty-two week high of $350.00. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period last year, the company posted $0.55 EPS. The business's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on PODD shares. Barclays upped their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, Truist Financial initiated coverage on Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.